Sigachi Industries Limited has announced a significant advancement in its research and development program with the successful progression of a Cystic Fibrosis (CF) active pharmaceutical ingredient (API) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The achievement represents a strategic step forward in the company’s expansion into complex, high-value specialty APIs serving global markets.
The development aligns with Sigachi’s long-term focus on differentiated therapeutic segments that feature high entry barriers and sustained demand. The global cystic fibrosis treatment market is estimated to exceed USD 10 billion, driven by increasing adoption of next-generation modulator therapies, chronic treatment needs, and pricing stability. Sigachi’s entry into this segment positions the company within a structurally resilient and innovation-driven market.
Based on internal assessments, Sigachi is actively evaluating strategic partnerships with formulation developers to support further research, regulatory progression, and eventual commercial supply of the CF APIs. Subject to successful collaborations and market readiness, the company estimates potential revenues of approximately ₹250 crore per annum beginning Q4 FY2026–27, making the CF portfolio a meaningful contributor to future growth.
The CF API combination involves sophisticated chemistry, multi-step synthesis processes, and specialized reactions, resulting in significant technological complexity. These factors create substantial barriers to entry, limiting competitive intensity and underscoring Sigachi’s growing capabilities in advanced API manufacturing. Adding to the long-term opportunity, patent protection for Vanzacaftor extends until 2039, providing extended visibility for collaboration-led commercialization within the cystic fibrosis therapeutic space.
Commenting on the milestone, Lijo Chacko, Deputy Group CEO of Sigachi Industries Limited, said the achievement reflects the company’s focused investment in complex APIs with durable growth potential. He added that Sigachi’s R&D strategy and partnership-driven approach are designed to build sustainable value while strengthening its position in high-entry-barrier segments.
Sigachi Industries continues to scale its innovation-led initiatives alongside its core businesses, maintaining a disciplined approach to long-term growth aligned with global healthcare needs. Sigachi Industries Limited operates globally in APIs, intermediates, excipients, vitamin and mineral blends, and operations and management services. The company runs manufacturing facilities in Telangana, Gujarat, and Karnataka, and maintains subsidiaries in the UAE and the United States. With more than three decades of industry experience, Sigachi serves pharmaceutical and nutraceutical customers across over 65 countries.
